flow trial semaglutide kidney outcomes nejm 2024 hazard ratio results 0.76 and Survival Benefits of in Diabetes With Chronic Kidney Disease: Cardiovascular Subgroup Analyses Semaglutide in Patients with Heart – FLOW- the flow trial semaglutide kidney outcomes

This new study, published in The investigators examined 17 unique NITs, including liver enzymes (ALT, AST), CK18 fragments, FibroScan-based metrics (controlled attenuation parameter and liver stiffness measure [LSM]), composite fibrosis scores (FIB-4, ELF, ADAPT), and proprietary biomarker panels such as NIS-4, MASEF, and several SomaSignal tests

Irene Romera: conception and design of the work

It works by mimicking a hormone that targets brain areas regulating appetite and food intake, helping to control hunger and create a feeling of fullness

While microdosing GLP-1s may be beneficial for a variety of reasons for certain individuals, the growing interest in microdosing GLP-1s can at least in part be tied to the significant metabolic shifts women experience during perimenopause and menopause

In dermatology, NO is implicated in mechanisms underlying inflammatory or immune-mediated dermatoses, skin infections, skin cancers, and wound healing (118)